NuVasive Gets a Buy Rating from BTIG

By Jason Carr

BTIG analyst Ryan Zimmerman maintained a Buy rating on NuVasive (NASDAQ: NUVA) yesterday and set a price target of $72. The company’s shares closed yesterday at $53.14.

According to, Zimmerman is a 5-star analyst with an average return of 36.0% and a 60.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.

NuVasive has an analyst consensus of Moderate Buy, with a price target consensus of $64.

See today’s analyst top recommended stocks >>

NuVasive’s market cap is currently $2.72B and has a P/E ratio of 34.51. The company has a book value ratio of 3.4185.

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NUVA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.